Pharmacological modulation of RB1 activity mitigates resistance to neoadjuvant chemotherapy in locally advanced rectal cancer.

MLA

Zhaoliang Yu, et al. “Pharmacological Modulation of RB1 Activity Mitigates Resistance to Neoadjuvant Chemotherapy in Locally Advanced Rectal Cancer.” Proceedings of the National Academy of Sciences of the United States of America, vol. 121, no. 6, Feb. 2024, pp. 1–12. EBSCOhost, https://doi.org/10.1073/pnas.2304619121.

APA

Zhaoliang Yu, Peng Deng, Yufeng Chen, Dezheng Lin, Shini Liu, Jinghan Hong, Peiyong Guan, Jianfeng Chen, Min-er Zhong, Jinghong Chen, Xiaochuan Chen, Yichen Sun, Yali Wang, Peili Wang, Zerong Cai, Yongsheng Chan, J., Yulin Huang, Rong Xiao, Yaoyu Guo, & Xian Zeng. (2024). Pharmacological modulation of RB1 activity mitigates resistance to neoadjuvant chemotherapy in locally advanced rectal cancer. Proceedings of the National Academy of Sciences of the United States of America, 121(6), 1–12. https://doi.org/10.1073/pnas.2304619121

Chicago

Zhaoliang Yu, Peng Deng, Yufeng Chen, Dezheng Lin, Shini Liu, Jinghan Hong, Peiyong Guan, et al. 2024. “Pharmacological Modulation of RB1 Activity Mitigates Resistance to Neoadjuvant Chemotherapy in Locally Advanced Rectal Cancer.” Proceedings of the National Academy of Sciences of the United States of America 121 (6): 1–12. doi:10.1073/pnas.2304619121.